State Street reports 6.4% stake in Syndax Pharmaceuticals
State Street Corporation reported a significant ownership position in Syndax Pharmaceuticals Inc. common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
State Street Corporation reported a significant ownership position in Syndax Pharmaceuticals Inc. common stock. State Street and its investment management subsidiaries reported that they beneficially own 5,658,465 shares of Syndax common stock, representing 6.4% of the class as of June 30, 2026. The filing states no sole voting or dispositive power, with shared voting power over 5,408,786 shares and shared dispositive power over 5,658,465 shares. The position is held through entities including SSGA Funds Management, Inc., State Street Bank and Trust Company, and several State Street Global Advisors entities. The filing notes that no other person is known to have rights to more than 5% of the class through this holding.
Key Figures
Key Terms
beneficially owned financial
Schedule 13G regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much of Syndax Pharmaceuticals (SNDX) does State Street Corporation own?
What voting power does State Street have in Syndax Pharmaceuticals (SNDX)?
Which State Street entities hold the Syndax Pharmaceuticals (SNDX) stake?
Does any other person have rights to more than 5% of SNDX through State Street’s holdings?
AI-generated analysis. How Rhea-AI works. Not financial advice.